TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Applications to Develop PET and SPECT Ligands for Brain Imaging Sought

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS) encourages small business innovation research (SBIR) and small business technology transfer (STTR) applications to develop positron emission tomography (PET) and single-photon emission computed tomography (SPECT) ligands for brain imaging.  This announcement is made together with 4 other components of the National Institutes of Health (NIH).*

Tremendous opportunities exist for using PET and SPECT imaging to study the pathophysiology and treatment of brain disorders, but relatively few radioligands are currently available for functional imaging of target molecules implicated in normal brain function and in brain and behavioral disorders.  This initiative is intended to stimulate the development of radioligands for molecular targets that are of broad interest to the scientific community.

Topics of interest include, but are not limited to:  lead compound identification/development and syntheses of chemicals with suitable binding affinity, biodistribution, pharmacokinetics, and physio-chemical properties allowing radiochemical synthesis; model development for quantitation, including development and evaluation of pharmacokinetic models and use of animal models of gradient of binding sites/enzymes to assess sensitivity to changes; investigational new drug (IND) application development and submission to the Food and Drug Administration (FDA) prior to pilot human studies; pilot human imaging studies with normal controls, pharmacological challenges with analyses of radiometabolites under the auspices of institutional review board (IRB) approval; and clinical studies in patient/disease population or experimental manipulations.

For more information, potential applicants should contact Dr. Daofen Chen, Program Director, Systems and Cognitive Neuroscience Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2131, Bethesda, MD  20892; telephone:  301-496-1917; fax:  301-402-1501; e-mail:

*For a full list of supporting NIH components and a more detailed description of this announcement, please visit the NIH web site at: (SBIR) or (STTR).